InMed Pharmaceuticals Inc (NASDAQ:INM) shares are trading higher by 22.6% to $6.05 during Tuesday’s session after the company announced that INM-901 reduced Alzheimer’s-related inflammation in a ...
Reduces key pro-inflammatory markers, independent of amyloid beta or tau pathology Vancouver, British Columbia--(Newsfile Corp. - June 24, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or ...
February 11, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug ...
InMed’s INM-901 Demonstrates Potential as a Multi-factorial Approach to Treating Alzheimer’s Disease
InMed Pharmaceuticals (Nasdaq:INM) recently released preclinical data indicating its proprietary, small molecule compound, INM-901, targets multiple biological pathways associated with Alzheimer’s ...
mRNA profile showed a reduction of several key neuroinflammatory genes in the brain Vancouver, British Columbia--(Newsfile Corp. - January 21, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" ...
InMed Pharmaceuticals Inc. (NASDAQ:INM) stock is surging early Tuesday, with a session volume of 6.63 million compared to the average volume of 1.31 million, as per data from Benzinga Pro. On Tuesday, ...
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed ...
What happened yesterday? The CEA began investigating INM after two senior executives, Robert Pitt and Ryan Preston, made allegations that Leslie Buckley, INM’s then chairman, had made efforts to ...
It is complicated, involves the biggest names in Irish business and raises significant governance issues. The unfolding developments at Independent News & Media this week are part of a serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results